Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BIOPOL CHEMICALS LTD.

NSE : BIOPOLBSE : ISIN CODE : INE0XW001014Industry : ChemicalsHouse : Private

BSE0.000 (0 %)

PREV CLOSE ( ) NA

OPEN PRICE ( ) 0.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 0

TODAY'S LOW / HIGH ( )0.00 0.00

52 WK LOW / HIGH ( )0 0

NSE92.00-0.65 (-0.7 %)

PREV CLOSE( ) 92.65

OPEN PRICE ( ) 92.00

BID PRICE (QTY) 92.50 (1200)

OFFER PRICE (QTY) 97.80 (1200)

VOLUME 1200

TODAY'S LOW / HIGH( ) 92.00 92.00

52 WK LOW / HIGH ( )84.75 111

Select year

Particulars

Mar 2025

Mar 2024

Operational & Financial Ratios

Earnings Per Share (Rs)

5.47

1.62

CEPS(Rs)

5.56

1.67

DPS(Rs)

0.00

Book NAV/Share(Rs)

17.10

11.63

Tax Rate(%)

25.40

25.19

Margin Ratios

Core EBITDA Margin(%)

13.30

10.76

EBIT Margin(%)

13.20

10.53

Pre Tax Margin(%)

11.81

9.82

PAT Margin (%)

8.81

7.35

Cash Profit Margin (%)

8.96

7.58

Performance Ratios

ROA(%)

17.69

7.31

ROE(%)

38.10

13.92

ROCE(%)

38.16

14.37

Asset Turnover(x)

2.01

0.99

Sales/Fixed Asset(x)

119.20

47.06

Working Capital/Sales(x)

3.52

1.95

Efficiency Ratios

Fixed Capital/Sales(x)

0.01

0.02

Receivable days

99.51

212.12

Inventory Days

66.67

128.41

Payable days

56.07

95.76

Valuation Parameters

PER(x)

0.00

PCE(x)

0.00

Price/Book(x)

0.00

Yield(%)

EV/Net Sales(x)

0.29

0.65

EV/Core EBITDA(x)

2.20

6.08

EV/EBIT(x)

2.23

6.21

EV/CE(x)

0.68

0.89

M Cap / Sales

0.00

Growth Ratio

Net Sales Growth(%)

181.82

0.00

Core EBITDA Growth(%)

249.40

0.00

EBIT Growth(%)

253.24

0.00

PAT Growth(%)

238.08

0.00

EPS Growth(%)

238.08

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.57

0.39

Current Ratio(x)

1.81

2.08

Quick Ratio(x)

1.12

1.34

Interest Cover(x)

9.52

14.80

Total Debt/Mcap(x)